Endometriosis is generally regarded as a benign disease but it does exhibit some characteristics reminiscent of malignancy. This raises the possibility that, like malignant diseases, the development of endometriosis may involve the acquisition of somatic genetic alterations in genes that regulate cell growth and differentiation. Studies over the past few years have substantiated this view with the identi®cation of a variety of genetic abnormalities usually only associated with malignancies. Our own studies have shown that genetic alterations, as shown by loss of heterozygosity, are relatively common in endometriosis implying that tumour suppressor gene inactivation is likely to be involved in the proliferation and maintenance of all endometriotic implants. We have also shown by DNA ®ngerprinting that endometriotic lesions found adjacent to ovarian cancers have a common lineage, reinforcing the compelling histological and epidemiological data that endometriosis is a precursor of endometrioid and clear cell ovarian cancers. It is now well accepted that susceptibility to endometriosis may also involve an inherited genetic component. Studies aimed at identifying the predisposing genes are still in their infancy but should eventually provide invaluable insights into the pathology and aetiology of endometriosis.
Introduction
Endometriosis is de®ned as a condition in which tissue histologically similar to endometrium is found at sites outside the uterine cavity. Very little is known about the underlying mechanisms that lead to the development of endometriosis which is remarkable given that it is one of the most common gynaecological diseases and may affect >10% of all premenopausal women (Mahmood and Templeton, 1991) . The aetiology of endometriosis is uncertain, but implantation of viable endometrium re¯uxed into the peritoneal cavity during menstruation and metaplasia of peritoneal epithelium are two major theories invoked to explain its origin (Thomas, 1993) . Although endometriosis generally follows a benign course, it does exhibit some characteristics reminiscent of malignancy, including local invasion and metastasis. A relationship between endometriosis and endometrioid and clear cell cancers of the ovary has long been suspected, based on their frequent co-occurrence in surgical specimens. A summary of the data from four recent large studies shows the frequency of endometriosis synchronous with ovarian cancer is 17%, with the vast majority of these being associated with endometrioid and clear cell sub-types (Table I) . In over a third of these cases, a clear transition from endometriosis to malignancy was observed. Based on clinically documented cases, the frequency of malignant transformation of ovarian endometriosis is 0.3±1.6% (Seidman, 1996) but the actual frequency is probably signi®cantly higher. In a long-term follow-up of >20 000 Swedish women hospitalized for endometriosis, a 1.9 relative risk of ovarian cancer was observed (Brinton et al., 1997) . The risk increased dramatically to 4.2 (95% con®dence interval 2.0±7.7) among subjects with a long-standing history of ovarian endometriosis.
Many of the risk factors associated with endometriosis and ovarian cancer are the same and include earlier menarche, more regular periods, shorter cycle lengths and lower parity. For endometriosis, the increased risk is consistent with an increased opportunity for menstrual contamination of the peritoneal cavity, while for ovarian cancer these factors are thought to increase the number of ovulations and, therefore, the potential for malignant transformation of damage epithelium. However, it is possible that part of the increased ovarian cancer risk is due to an increased risk of endometriosis-associated endometrioid and clear cell sub-types. This idea is supported by others authors (Rosenblatt and Thomas, 1996) who found that tubal ligation, which prevents menstrual re¯ux and is protective for endometriosis, was also protective for clear cell and endometrioid ovarian cancers (relative risks of 0.2 and 0.32) but not serous and mucinous cancers. Although much of the data is circumstantial, there does appear to be a strong case for suggesting that endometriosis has malignant potential and is the precursor of some, and possibly all, endometrioid and clear cell ovarian cancers.
Somatic genetics of endometriosis
In the past few years, molecular genetic studies of cancer have revealed that genetic alterations in oncogenes and tumour suppressor genes (TSGs) are central to the development of malignant tumours as well as their precursors. Both ourselves and others have postulated that similar alterations may occur during the development and progression of endometriosis. However, few studies have searched for genetic alterations that may be occurring in endometriosis. Evidence for the involvement of genetic abnormalities in endometriotic cells was provided by demonstrating DNA aneuploidy in three out of six cysts with severe atypia (Ballouk et al., 1994) and it was suggested that these cells represent precursors of the invasive malignancies that may arise in ovarian endometriotic cysts. In a multicolour¯uorescence in-situ hybridization study, one group (Shin et al., 1997) observed chromosome 16 and 17 monosomy and trisomy of chromosome 11 in a small number of endometriotic cysts. However, in one study of 42 cases (Dangel et al., 1994) no cytogenetic abnormalities were observed, suggesting that such gross genetic alterations may not be particularly common or are restricted to more advanced lesions. It is likely that if pathologically relevant somatic genetic alterations are occurring their detection will require analytical techniques with a higher resolving power.
An indication that speci®c TSG inactivation may be important was suggested by an immunohistochemical study (Kupryjanczyk et al., 1993) which found p53 over-expression in a poorlydifferentiated endometrioid carcinoma as well as in adjacent benign endometriotic tissue. However, using a genetic mutation screening approach, other authors (Vercellini et al., 1994) were not able to detect TP53 or KRAS2 mutations in 10 endometriotic cysts. In the mid-1990s, the literature cited above represented virtually all that was known about the somatic genetics of endometriosis. At that time, molecular genetic studies of malignant diseases were providing important insights into their aetiology and pathogenesis and it was clear that a similar study of endometriosis was needed. Consequently, over the past 5 years our own laboratory has been using polymerase chain reaction (PCR)-based techniques as a means of identifying somatic genetic alterations in endometriosis. Our studies, and some other recent investigations (Kosugi et al., 1999) now indicate that somatic genetic alterations may be fundamental for the initiation, persistence and progression of endometriosis.
Endometriosis and ovarian cancer
The data cited above, together with epidemiological and histological evidence accumulated over many years, supported the idea that endometriosis was the precursor to endometrioid and clear cell ovarian cancer. Nevertheless, no study was able to provide conclusive genetic evidence in support of a common lineage between endometriosis and ovarian cancer. To provide unequivocal data linking endometriosis with ovarian cancer we applied molecular genetic analysis coupled with tissue microdissection to assess the relationship between endometriotic foci found adjacent to, or contiguous with, ovarian cancers . Our principal tool in this investigation was loss of heterozygosity (LOH) analysis which detects DNA deletions that are the hallmark of TSG inactivation. A summary of some of the key LOH data from Jiang et al. (1998) are shown in Table II . We detected 17 LOH events in the endometriosis components of nine of the 11 cases examined and importantly all 17 losses were also found in the adjacent carcinoma components. All four cases where the carcinoma appeared to arise within the endometriotic cysts (cases 38, 78, 108, and 267) displayed at least two common LOH events and case 38, in particular, showed three common LOH events on chromosome arms 9p, 11q and 22q. Five of the seven cases with carcinoma adjacent to the endometriosis also displayed common LOH events. The probability that the common LOH events represented independent events was calculated (Jacobs et al., 1992; Abeln et al., 1995) ; for the majority P u Â 0.05, indicating that it was very unlikely that the synchronous endometriosis and carcinoma components arose independently. This data strongly supports the hypothesis that endometriosis is the precursor to endometrioid ovarian cancers.
In some ways it was not too surprising to ®nd LOH in endometriosis that had clearly undergone malignant transformation. The key question remaining was whether TSG inactivation was involved in the aetiology of all endometriosis and not just that associated with ovarian cancer. Initially we analysed for LOH on chromosome arms 2q, 5q, 6q, 7p, 9p, 11q, 17p, 17q, and 22q, since these chromosomes were thought to harbour TSGs involved in the development of ovarian cancer (Cliby et al., 1993; Osborne and Leech, 1994) . Our ®rst study of 40 cases identi®ed 11 (28%) with LOH at one or more loci on chromosome arms 9p, 11q and 22q (Jiang et al., 1996) demonstrating for the ®rst time that inactivation of TSGs was likely to be integral to the development of all endometriosis. As yet the genes which are the target of the LOH have not been positively identi®ed but it is possible that the LOH on chromosome 9p21 is related to loss or down-regulation of the CDKN2 tumour suppressor gene. We have not detected CDKN2 genetic mutations in more than 40 cases studied (unpublished observations) and, to date, none have been reported in the literature. However, it is interesting to note that loss of CDKN2 expression is relatively common among endometrioid ovarian cancers (Milde-Langosch et al., 1998) .
A molecular genetic model of endometriosis development
When our LOH data for endometriosis with and without adjacent carcinoma is compared with LOH data for endometrioid ovarian cancers a striking trend is evident (Table III) . The four chromosome arms showing LOH in solitary endometriosis were also the ones most frequently lost in endometriosis synchronous with carcinoma, and each of these chromosome arms showed a high frequency of LOH in low grade and early stage endometrioid ovarian cancer. The increasing trend of LOH in solitary endometriosis, endometriosis with synchronous carcinoma and The location of the endometriosis with atypia and/or carcinoma relative to the endometriosis; w = within the carcinoma; a = adjacent to the carcinoma. b Clonality with respect to the endometriosis: same, endometriosis and carcinoma are monoclonal and show the same X-chromosome inaction; different, endometriosis and carcinoma are monoclonal but show the opposite X-chromosome inactivation pattern; blank space = not informative; dnw = did not work; ni = not informative; nd = not done. endometrioid ovarian carcinoma on chromosome arms 5q, 9p, 11q and 22q lends further support to the hypothesis that each of these represents a continuum of the same disease. As a result of these studies we are in a position to propose a genetic model for the development and malignant transformation of endometriosis. The ®rst step is the implantation of ectopic endometrium, which then proliferates to produce a monoclonal endometriotic cyst. It is not known whether implantation is dependent upon the presence of genetic alterations in these cells but we have shown that by the time these have developed into small endometriotic cysts over a third will harbour LOH, predominantly on chromosomes 9p, 11q or 22q (Jiang et al., 1996) . Since the majority of endometriotic cysts remain benign, these genetic alterations may only be involved in the maintenance of endometriotic cysts, with further mutations being required for promotion to a premalignant state. The detection of LOH on chromosome 5q in 6% of solitary endometriotic lesions and 25% of those found adjacent to ovarian cancer suggests that a gene on 5q might be associated with this promotion. LOH on chromosome 6q ®rst appears in endometriosis with adjacent carcinoma (27% of these cases) and this might be involved in malignant transformation. It is interesting to note that deletions involving chromosome 6q are very common in early ovarian cancers of all histological types (Tibiletti et al., 1996) and these authors have suggested that this may be one of the earliest lesions in the pathogenesis of ovarian cancer. LOH on chromosome 5q, 9p, 11q, and 22q are also common in early stage and/or low grade endometrioid ovarian cancers consistent with the pattern observed in endometriosis. In addition to these chromosomes LOH in early endometrioid ovarian cancer is particularly frequent on 17p and Xq suggesting that these regions may harbour genes involved in tumour progression. This proposal is by no means a de®nitive description of the molecular genetic events in the aetiology of endometriosis since we and others have analysed relatively few cases and only a limited number of chromosomal loci. Our purpose is simply to demonstrate that the bulk of histological, epidemiological and genetic data are consistent with the hypothesis that endometriosis may undergo malignant transformation to endometrioid and clear cell ovarian cancers and that somatic genetic alterations are integral to the proliferation of all endometriosis.
Genetic susceptibility to endometriosis
It is likely that heritable genetic factors contribute to the development of endometriosis (Kennedy et al., 1995; Had®eld et al., 1997; Treloar et al., 1999) . Although the genetic risk may be due to a single highly penetrant gene, it is more likely to be due to a number of genes each responsible for a small incremental increase in risk. One of the ®rst genetic risk factors to be investigated was the gene encoding for galactose-1-phosphate uridyl transferase (GALT). This gene is responsible for catalysing the production of glucose-1-phosphate and uridyl diphosphategalactose from galactose-1-phosphate and uridyl diphosphateglucose and constitutes the main pathway of galactose metabolism in humans (Reichardt and Woo, 1991) . Impairment of the GALT gene can lead to an accumulation of galactose and other metabolites, particularly galactose-1-phosphate which among other traits has been associated with premature ovarian failure (Kaufman et al., 1981) . In animal models, ovarian failure resulting from oocyte depletion invariably leads to ovarian cancer and a similar mechanism has been proposed for humans. The biological basis for this stems from observations that fetal or maternal mutations that decrease GALT activity are associated with vaginal agenesis in humans (Cramer et al, 1996a) . Such defects are thought to obstruct menstrual out¯ow and lead to increased retrograde menstruation, which is a well documented and signi®cant risk factor for endometriosis (van der Linden, 1996) . One group (Cramer et al., 1989 (Cramer et al., , 1994 ®rst reported an association with galactose consumption and metabolism and ovarian cancer risk. Subsequently, the same group (Cramer et al., 1996b) reported an association between the N314D mutation of GALT and women with endometriosis and in women with endometrioid and clear cell ovarian cancer (Cramer et al., 1997) . Although such an association was biologically plausible it was based on small numbers of highly selected cases. Our own investigations of the frequency of the N314D and Q188R GALT mutations among 78 endometriosis and 206 ovarian cancers (Table IV) did not substantiate the association of the GALT mutations with either endometriosis or endometrioid and clear cell ovarian cancers . However, we were able to con®rm an association with serous, mucinous and undifferentiated epithelial ovarian cancers, and demonstrate borderline signi®cance (P = 0.0782) with mucinous ovarian cancers. In the cancer ®eld many genes are being investigated as potential low penetrance predisposing genes (Dunning et al., 1999) and some of these are now being investigated in endometriosis. Investigation of the frequency of common inactive variants of the phase II detoxi®cation system genes, GSTM1, GSTT1 and NAT2, have recently been reported (Baranova et al., 1997 (Baranova et al., , 1999 . These authors observed a signi®cant excess of NAT2 slow acetylators and a highly signi®cant excess of the GSTM null genotype among women with endometriosis (76.9%) compared with controls (45.8%). Their data may suggest a possible contribution of environmental toxins in the pathogenesis of endometriosis. However it must be emphasised that their conclusions were based on relatively few cases (65) and studies of this size are notoriously prone to producing spurious statistical associations. Nevertheless the associations are very striking and clearly warrant further investigation.
As with normal endometrium, endometriosis is endocrinedependent and its growth is stimulated by oestrogen. In view of this, genetic variants of genes involved in oestrogen biosynthesis, degradation and signalling are all plausible risk factors. One group (Georgiou et al., 1999) investigated possible associations of endometriosis with two polymorphic variants in the oestrogen receptor among 57 cases compared with 57 controls. They observed an excess in a PvuII restriction site positive polymorphism and a signi®cant difference in the median number of (TA) n multiallele polymorphic repeats in endometriosis. The biological basis for these putative associations is unknown but the PvuII positive allele has been associated with a low production of oocytes per follicle and fewer pregnancies (Georgiou et al., 1997) which is consistent with the hypothesis that endometriosis susceptibility genes may be the same as those associated with infertility (Had®eld et al., 1997) .
The search for genes responsible for inherited susceptibility to endometriosis is in its infancy and the few candidate gene studies that have been reported (including our own) are limited in that they are based on a small number of often highly selected cases. Studies such as the Oxford Endometriosis Gene (OXEGENE) project (Kennedy, 1999) are overcoming these limitations through an international collaborative effort. They aim to identify susceptibility loci through linkage studies and then identify the actual genes through positional cloning. The results of the OXEGENE study may take some years to complete but should provide invaluable insights into the pathology and aetiology of endometriosis.
In conclusion it is now clear that we will not achieve a complete understanding of the aetiology and pathogenesis of endometriosis unless we incorporate a detailed description of the somatic and inherited genetic alterations present and an appreciation of how these interact with environmental and physiological factors.
